PMID- 36856851
OWN - NLM
STAT- MEDLINE
DCOM- 20230731
LR  - 20240416
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 149
IP  - 10
DP  - 2023 Aug
TI  - Based on ARASENS trial: efficacy and safety of darolutamide as an emerging option 
      of endocrinotherapy for metastatic hormone-sensitive prostate cancer-an updated 
      systematic review and network meta-analysis.
PG  - 7017-7027
LID - 10.1007/s00432-023-04658-6 [doi]
AB  - PURPOSE: The newly published ARASENS trial has demonstrated the clinical efficacy 
      of darolutamide for metastatic hormone-sensitive prostate cancer (mHSPC). 
      However, the use of darolutamide as the latest first-line androgen receptor 
      pathway inhibitor for mHSPC has not been compared with other androgen receptor 
      targeted agents (ARTAs). Given the lack of head-to-head randomized trials, we 
      performed this updated meta-analysis to conduct indirect comparison for the 
      efficacy and safety of darolutamide with other new-generation ARTAs. METHODS: By 
      searching the databases of PubMed, Scopus, Cochrane Library, and Embase, 9 large 
      randomized controlled trials evaluating ARTAs for mHSPC patients were eventually 
      screened according to PRISMA. We extracted data from overall survival, 
      castration-resistant progression, and adverse events for network meta-analysis 
      using the Bayesian and standard frequentist models. RESULTS: Darolutamide 
      combination emerged with superiority (HR = 0.68, 95%CrI = 0.57-0.81) among four 
      androgen receptor inhibitors for patients with high Gleason score (HR = 0.71, 
      95%CrI = 0.59-0.86). Darolutamide was best tolerated in several androgen 
      suppression-related adverse events (AEs). CONCLUSION: Darolutamide appears to be 
      an optional androgen receptor inhibitor for mHSPC patients, especially for 
      patients with Gleason score >/= 8. Its well-tolerated characteristic may provide a 
      preferred drug option for patients with poor cardiovascular function and bone 
      health.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Dou, Maoyang
AU  - Dou M
AD  - Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong 
      Province, China.
FAU - Liang, Hao
AU  - Liang H
AD  - Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong 
      Province, China.
FAU - Liu, Yang
AU  - Liu Y
AD  - Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong 
      Province, China.
AD  - Department of Urology, Weifang People's Hospital, Weifang Medical University, 
      Weifang, Shandong, China.
FAU - Zhang, Qiujie
AU  - Zhang Q
AD  - Department of Health Care, Qilu Hospital of Shandong University, Jinan City, 
      Shandong Province, China.
FAU - Li, Ruowen
AU  - Li R
AD  - Department of Hernia and Abdominal Wall Surgery, Qilu Hospital of Shandong 
      University, Jinan City, Shandong Province, China.
FAU - Chen, Shouzhen
AU  - Chen S
AD  - Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong 
      Province, China. chenshouzhen1990@163.com.
FAU - Shi, Benkang
AU  - Shi B
AD  - Department of Urology, Qilu Hospital of Shandong University, Jinan City, Shandong 
      Province, China. bkang68@sdu.edu.cn.
LA  - eng
GR  - 81800672/National Natural Science Foundation of China/
GR  - 81900637/National Natural Science Foundation of China/
GR  - 2019GSF108123/Primary Research & Development Plan of Shandong Province/
GR  - ts201511092/Taishan Scholar Foundation of Shandong Province/
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20230301
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Receptors, Androgen)
RN  - 0 (darolutamide)
RN  - 0 (Androgen Receptor Antagonists)
RN  - 0 (Hormones)
RN  - 0 (Androgen Antagonists)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Receptors, Androgen/metabolism
MH  - *Prostatic Neoplasms, Castration-Resistant/drug therapy/pathology
MH  - Network Meta-Analysis
MH  - Bayes Theorem
MH  - Androgen Receptor Antagonists/adverse effects
MH  - Hormones
MH  - Androgen Antagonists/therapeutic use
MH  - Randomized Controlled Trials as Topic
OTO - NOTNLM
OT  - Androgen receptor targeted agents
OT  - Androgen suppression
OT  - Darolutamide
OT  - Network meta-analysis
OT  - mHSPC
EDAT- 2023/03/02 06:00
MHDA- 2023/07/31 06:43
CRDT- 2023/03/01 11:15
PHST- 2022/12/06 00:00 [received]
PHST- 2023/02/16 00:00 [accepted]
PHST- 2023/07/31 06:43 [medline]
PHST- 2023/03/02 06:00 [pubmed]
PHST- 2023/03/01 11:15 [entrez]
AID - 10.1007/s00432-023-04658-6 [pii]
AID - 10.1007/s00432-023-04658-6 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2023 Aug;149(10):7017-7027. doi: 
      10.1007/s00432-023-04658-6. Epub 2023 Mar 1.